Compounded mAbs - Cancer Therapies

Phamacy Procurement Contract - A ranked framework for the supply and delivery of Compounded Monoclonal Antibodies (mAbs) for Intravenous Infusion for Chemotherapy indications split into 2 lots:

Lot 1: High Volume Products - 5 molecules / all brands

Lot 2: Lower Volume Products - 13 molecules / all brands

The ranked framework will be open to the participating Trusts of the South East Pharmacy Procurement Service (SEPPS):

Thames Valley and Wessex (TV&W)

1. Buckinghamshire Healthcare NHS Trust
2. Frimley Health NHS Foundation Trust
3. Hampshire Hospitals NHS Foundation Trust
4. Isle of Wight NHS Trust
5. Hampshire and Isle of Wight Healthcare NHS Foundation Trust
6. Milton Keynes University Hospital NHS Foundation Trust
7. Oxford Health NHS Foundation Trust
8. Oxford University Hospitals NHS Foundation Trust
9. Portsmouth Hospitals NHS Trust
10. Royal Berkshire NHS Foundation Trust
11. University Hospital Southampton NHS Foundation Trust

South-East Coast (SEC)

12. Ashford and St. Peters’ Hospitals NHS Foundation Trust
13. Dartford and Gravesham NHS Trust
14. East Kent Hospitals University NHS Foundation Trust
15. East Sussex Healthcare NHS Trust
16. Kent Community Health NHS Trust
17. Maidstone & Tunbridge Wells NHS Trust
18. Medway NHS Foundation Trust
19. Queen Victoria Hospitals NHS Foundation Trust
20. Royal Surrey County Hospital NHS Foundation Trust
21. Surrey and Borders Partnership NHS Foundation Trust
22. Surrey and Sussex Healthcare NHS Trust
23. Sussex Community NHS Trust
24. Sussex Partnership NHS Foundation Trust
25. University Hospitals Sussex NHS Foundation Trust
26. Berkshire Healthcare NHS Foundation Trust

This framework will be available for use by Trusts in East of England and London regions, but the volumes for these regions have not been included for adjudication as part of the tender process.

SEC Trusts can utilise this tender for products or services not covered by the National unlicensed aseptically prepared cytotoxic medicines and mAbs framework via MPSC.

Please note: we did not publish a preliminary market engagement notice (UK2) for the following reasons:

• we are not seeking to further develop our requirements or procurement approach.
• we have procured similar supply arrangements via the Open procedure and deployed similar conditions of participation and award criteria. These have yielded good results previously.
• we have already prepared our tender pack (see attached), that detail standard NHS contractual terms which have been found to be acceptable to the supply chain.
• we understand the likely suppliers who will be interested but the open notice approach gives opportunity to others looking to enter the mAbs supply market